logo

Omeros Corp. (OMER)



Trade OMER now with
  Date
  Headline
8/10/2018 5:41:24 PM Wedbush Reiterates Omeros Corp. (OMER) At Neutral With $20 Price Target
7/26/2018 7:39:20 AM Sandoz Amends ANDA To Not Seek Approval For Generic Version Of OMIDRIA Until Patents For Omeros’ Drug Expire
7/25/2018 8:42:58 AM Omeros’ OMS721 Gets EU Orphan Drug Designation Positive Opinion For Treatment In Hematopoietic Stem Cell Transplantation
7/23/2018 7:15:51 AM Omeros Corporation Initiates Sales Of OMIDRIA In Europe
7/17/2018 7:03:05 AM Omeros Initiates Dosing In Phase 1 Trial For OMS527 Targeting Addiction
7/17/2018 7:02:18 AM Omeros Initiates Dosing In Phase 1 Clinical Trial For OMS527 Targeting Addiction
6/27/2018 9:16:23 AM Omeros Secures Approval To Begin Phase 1 Clinical Trial For Its OMS527 Addiction Treatment
5/24/2018 7:03:06 AM Omeros Announces Settlement Of Infringement Suit Against ANDA Filer Lupin
5/1/2018 3:35:57 PM Wedbush Reiterates Omeros Corp. (OMER) At Neutral With $19 Price Target
3/23/2018 7:31:05 AM Wedbush Is Lowering Omeros Corp. (OMER) FY18 Rev. Estimate To 9.5 M From 121.5 M
3/23/2018 7:30:40 AM Wedbush Is Cutting Omeros Corp. (OMER) Q4 18 Rev. Estimate To 3.4 M From 36.1 M
3/23/2018 7:30:28 AM Wedbush Is Lowering Omeros Corp. (OMER) Q3 18 Rev. Estimate To 2.6 M From 31.5 M
3/23/2018 7:29:47 AM Wedbush Is Lowering Omeros Corp. (OMER) Q2 18 Rev. Estimate To 2.0 M From 28.6 M
3/23/2018 7:29:13 AM Wedbush Is Lowering Omeros Corp. (OMER) Q1 19 Rev. Estimate To 1.5 M From 25.3 M
3/23/2018 7:28:36 AM Wedbush Is Lowering Omeros Corp. (OMER) FY18 Estimate To -2.03 From -0.24
3/23/2018 7:28:07 AM Wedbush Is Lowering Omeros Corp. (OMER) Q4 18 Estimate To -0.50 From 0.02